Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766524 | 0.89 | HIF1A (0.48) | HIF1APNPLMNATP53HTT | |
| SCHEMBL3771295 | 0.88 | HIF1A (0.48) | HIF1APNPLMNATP53HTT | |
| SCHEMBL11688219 | 0.87 | HIF1A (0.63) | HIF1APNPLMNATP53HTT | |
| SCHEMBL20129803 | 0.87 | HIF1A (0.63) | HIF1APNPLMNATP53HTT | |
| SCHEMBL29738724 | 0.87 | HIF1A (0.63) | HIF1APNPLMNATP53HTT | |
| SCHEMBL11688227 | 0.87 | HIF1A (0.63) | HIF1APNPLMNATP53HTT | |
| SCHEMBL887520 | 0.87 | HIF1A (0.63) | HIF1APNPLMNATP53HTT | |
| SCHEMBL10022903 | 0.87 | HIF1A (0.63) | HIF1APNPLMNATP53HTT | |
| SCHEMBL7661650 | 0.85 | HIF1A (0.52) | HIF1APNPLMNATP53HTT | |
| SCHEMBL27218348 | 0.85 | PNP (0.64) | HIF1APNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847075-B2 | 2-Azapurine compounds and their use | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090306360-A1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-7612187-B2 | 2-azapurine compounds and their uses | ROCHE DIAGNOSTICS, GMBH (DE) | 2009-11-03 | — | — | US | disclosed |
| US-7169553-B1 | 2-Azapurine compounds and their use | ROCHE DIAGNOSTICS, GMBH (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20070015725-A1 | 2-azapurine compounds and their uses | ROCHE DIAGNOSTICS, GMBH (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1214331-B1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306360-A1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ADAR, AMPD2, NSUN2 | HIF1A 3667/4885PNP 63/4885LMNA 4166/4885 |
| US-20070015725-A1 | 2-azapurine compounds and their uses | ADAR, NSUN2, AMPD2 | HIF1A 3580/4885PNP 65/4885LMNA 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.